vimarsana.com

Page 2 - தலை ஆஃப் ஆராய்ச்சி வளர்ச்சி News Today : Breaking News, Live Updates & Top Stories | Vimarsana

APEIRON Biologics Announces Changes to Management and Supervisory Boards

APEIRON Biologics Announces Changes to Management and Supervisory Boards DGAP-News: APEIRON Biologics AG / Key word(s): Personnel 01.06.2021 / 10:00 APEIRON Biologics Announces Changes to Management and Supervisory Boards Management Board to be expanded by Romana Gugenberger, PhD, as Chief Medical & Scientific Officer (CMSO) and Andreas Gerber, PhD, as Chief Operating Officer (COO) Prof. Josef Penninger moves from the Supervisory Board to the newly created Scientific Advisory Board, which he will build up and lead as Chairman APEIRON to propose Ulrich Granzer PhD as new member of the Supervisory Board at the upcoming Annual General Meeting Vienna, Austria, 1 June 2021: APEIRON Biologics AG, a privately held biotechnology company developing novel immunotherapies for cancer and respiratory diseases, today announced changes to the Company s Management and Supervisory Boards.

Modular Real-Time Monitoring in Pharmaceutical Cold Chain, Upcoming Webinar Hosted by Xtalks

NutraIngredients Immunity Series: Join us live today as we shine the spotlight on botanicals in APAC

NutraIngredients Immunity Series: Join us live today as we shine the spotlight on botanicals in APAC NutraIngredients interactive and FREE broadcast series focusing on immunity continues today, with the second APAC edition detailing the thriving botanicals category. This year’s series features 10 broadcasts, with three coming from NutraIngredients-Asia’s regional HQ in Singapore. The first, assessing clinical trials, is now available to view on demand.​ The second, on botanicals, take place on May 11 at 3pm SGT. NutraIngredients-Asia Editor-in-Chief Gary Scattergood said:  “With consumer demand for immunity-boosting products soaring, this series will bring together leading experts to assess the existing scientific evidence, the scope for new product development, the opportunity for gold-standard clinical research, and the marketing and regulatory challenges across the region.”​

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.